You are here

EASIER TO CONJUGATE TO ANTIBODIES WITH HIGHER REPRODUCIBILITY.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 2985
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1985
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
130 Fifth Avenue North
Seattle, WA 98109
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HARRY W. SNYDER, JR.
 PRINCIPAL INVESTIGATOR
 (206) 448-1000
Business Contact
Phone: () -
Research Institution
N/A
Abstract

EASIER TO CONJUGATE TO ANTIBODIES WITH HIGHER REPRODUCIBILITY.THE AIM OF THIS RESEARCH IS TO ISOLATE AND CHARACTERIZE ANTIGENS IN CIRCULATING IMMUNE COMPLEXES (CIC) FROM PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME AND KAPOSI'S SARCOMA (AIDS-KS) AND TO EXPLOIT THESE ANTIGENS FOR DEVELOPMENT OF NEW DIAGNOSTIC AND PROGNOSTIC REAGENTS. ELUATES FROM COLUMNS OF STAPHYLOCOCCUS AUREUSCOWAN I PROTEIN A BOUND TO A SILICA MATRIX (PROSORBATM), WHICH HAVE BEEN PERFUSED WITH UP TO 2 LITERS OF PATIENT PLASMA AS PART OF A THERAPEUTIC PROTOCOL. ELUATES FROM 60 PROCEDURES HAVE BEEN COLLECTED AND OVER 300 OTHER ELUATES WILL BE COLLECTED IN THE NEXT 6 MONTHS. CIC AND IGG CAN BE ELUTED FROM PROSORBA COLUMNS AND THE CIC CAN BE PURIFIED BY SUCROSE GRADIENT ULTRACENTRIFUGATION. ANTIGEN AND ANTIBODY CAN THEN BE SEPARATED BY CENTRIFUGATION OF CIC IN SUCROSE GRADIENTS UNDER CONDITIONS FAVORING DISSOCIATION OF COMPLEXES. A COMMON ANTIGEN HAS BEEN ISOLATED FROM CIC IN 3 AIDS-KS PATIENTS; THE SAME ANTIGEN WAS NOT FOUND IN CIC OBTAINED FROM PATIENTS WITH OTHER MALIGNANCIES AND NORMALS. DURING PHASE I OF THE PROPOSED RESEARCH, HETEROLOGOUS ANTISERUM WILL BE RAISED AGAINST THIS CIC-DERIVED ANTIGEN AND IMMUNOLOGIC SCREENS OF SERA FROM NUMEROUS CANCER PATIENTS AND NORMALS WILL BE PERFORMED TO ASSESS THE DISTRIBUTION OF THE ANTIGEN. PHASE II OF THE PROPOSAL WILL INVOLVE MORE EXTENSIVE SPECIFICITY TESTING, DEVELOPMENT OF MONOCLONAL ANTIBODIES AGAINST THE ANTIGEN, LOCATION OF CELL LINES EXPRESSING THE ANTIGEN FOR PRODUCTION PURPOSES, AND DEVELOPMENT OF A TEST KIT FOR CLINICAL APPLICATION. A TEST FOR A SEROLOGIC MARKER FOR AIDS-KS WOULD MAKE A MAJOR CONTRIBUTION TO THE CLINICAL EVALUATION AND MANAGEMENT OF THIS DISEASE.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government